Health Care Resource Utilization and Costs Associated with US Medicaid Sobriety Restrictions on Direct-Acting Antivirals for Hepatitis C Virus: A Retrospective Claims Database Analysis
Patients who initiated DAAs with SR versus NSR had 2 times and 1.5 times greater likelihood of IP and OP visits, respectively. Similarly, the SR versus NSR cohort had 3 times greater medical costs. Restricting DAA access among patients with HCV increases HCRU and cost burden, potentially impeding World Health Organization (WHO) 2030 HCV global elimination goals.
Authors
- Marvin Rock
- Krithika Rajagopalan (ORCID: https://orcid.org/0000-0002-4878-0822)
- Caroline Burk (ORCID: https://orcid.org/0009-0002-0456-7058)
- Michelle T. Martin (ORCID: https://orcid.org/0000-0003-3960-5616)
- Nancy S. Reau (ORCID: https://orcid.org/0000-0003-2290-4580)
- Alice Hsiao
- Fatema Turkistani
- Dilip Makhija
Institutions
- Rush University Medical Center (US)
- American Society for Neurochemistry (US)
- University of Illinois Chicago (US)
- Gilead Sciences (United States) (US)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2025-05-28
- DOI
- https://doi.org/10.1007/s40273-025-01487-y
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences